Asundexian versus Apixaban in Patients with Atrial Fibrillation
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with...
NEJM at ESC — Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual...
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual...
Atrial Fibrillation and Stable Coronary Artery Disease
Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without...
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
